# HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis

> **NCT00932971** · PHASE2 · COMPLETED · sponsor: **HepNet Study House, German Liverfoundation** · enrollment: 70 (actual)

## Conditions studied

- Hepatitis D

## Interventions

- **DRUG:** PEG-IFN alfa-2a, Tenofovir
- **DRUG:** PEG-IFN alfa-2a, placebo

## Key facts

- **NCT ID:** NCT00932971
- **Lead sponsor:** HepNet Study House, German Liverfoundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2017-08
- **Final completion:** 2017-08-02
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2018-01-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932971, "HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00932971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*